Homœopathic Links 2021; 34(03): 191-198
DOI: 10.1055/s-0041-1735489
Original Article

Homoeopathic Treatment in Hypothyroidism—An Open-Label, Prospective, Single-Arm, Clinical Trial

Aniket Singha Ray
1   Department of Organon of Medicine and Homoeopathic Philosophy, D.N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
,
Subhasish Ganguly
1   Department of Organon of Medicine and Homoeopathic Philosophy, D.N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
,
Shyamal Kumar Mukherjee
2   Principal, D.N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
,
Pallavi Hazra
1   Department of Organon of Medicine and Homoeopathic Philosophy, D.N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
,
1   Department of Organon of Medicine and Homoeopathic Philosophy, D.N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
,
Arunava Nath
3   Deptartment of Forensic Medicine & Toxicology, Pratap Chandra Memorial Homoeopathic Hospital and College, Kolkata, West Bengal, India
,
Munmun Koley
4   Department of Organon of Medicine and Homoeopathic Philosophy, National Homoeopathic Medical College, Lucknow, Uttar Pradesh, India
,
Subhranil Saha
5   Department of Repertory, D.N.De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
› Institutsangaben
Preview

Abstract

Background Hypothyroidism is one of the most common endocrinal disorders in India and its incidence is gradually increasing. A preliminary clinical trial was conducted to assess the probable role of individualised homoeopathic (IH) medicines in hypothyroidism with the assessment of hormonal titre (serum thyroid-stimulating hormone [TSH] and free T4) and symptomatic improvement.

Methods An open-label, prospective, single-arm trial was conducted on 40 patients suffering from hypothyroidism at the outpatient of D. N. De Homeopathic Medical College and Hospital, West Bengal, India, and treated with IH. Serum TSH and FT4 were considered as the primary outcomes and Zuleswki's clinical scoring (ZCS) and thyroid symptom questionnaire (TSQ) as the secondary outcomes, measured at baseline and after 3 months of treatment. Intention-to-treat sample was analysed in the end by paired t-tests.

Results Total 58 patients were screened, of which 40 patients were enrolled; 4 patients dropped out, 36 patients completed the trial. Mean age was 44 years (standard deviation: 13.6), and majority of the patients were female (87.5%). Improvement in both primary and secondary outcomes was statistically significant (p <0.001, paired t-tests), TSH (mean reduction: 2.7, 95% confidence interval [CI]: 1.9–3.6, p = 0.001), FT4 (mean increase: −0.2, 95% CI: −0.3 to −0.2, p = 0.001), ZCS (mean reduction: 3.7, 95% CI: 2.9–4.6, p = 0.001), and TSQ (mean reduction: 2.9, 95% CI: 2.1–3.6, p = 0.001). Most frequently used medicines were Sulphur (20%), Pulsatilla nigricans (12.5%), Iodium (10%), Phosphorus (10%), and Natrum muriaticum (7.5%).

Conclusion This study showed promising treatment effects of IH in hypothyroidism. Randomised trials are warranted (Trial registration: CTRI/2018/11/016451; UTN: U1111–1223–2292).

Authors' Contribution

ASR, SG, SKM, PH, and SD were involved in concept, literature search, clinical study, data acquisition, data interpretation, and preparation of the article; AN, MK, and SS were involved in concept, literature search, design, data interpretation, statistical analysis, and preparation of the article. All the authors reviewed and approved the final paper.


Ethical Approval

The study protocol was approved by the IEC (Ref. No. DHC/Aca(PG)29/14/861/18) dated 13 September 2018 and was registered prospectively in the Clinical Trials Registry—India (Trial registration: CTRI/2018/11/016451; UTN: U1111–1223–2292).


Financial Support

Nil.




Publikationsverlauf

Artikel online veröffentlicht:
10. Dezember 2021

© 2021. Thieme. All rights reserved.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India